OnKure Therapeutics
OKUR
33 hedge funds and large institutions have $43.3M invested in OnKure Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.73% less ownership
Funds ownership: 70.7% → 66.97% (-3.7%)
15% less capital invested
Capital invested by funds: $50.8M → $43.3M (-$7.49M)
20% less funds holding
Funds holding: 41 → 33 (-8)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$402K |
| 2 |
Millennium Management
New York
|
+$139K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$124K |
| 4 |
Barclays
London,
United Kingdom
|
+$117K |
| 5 |
E
Ergoteles
New York
|
+$98.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tybourne Capital Management
Hong Kong
|
-$2.06M |
| 2 |
BlackRock
New York
|
-$684K |
| 3 |
State Street
Boston,
Massachusetts
|
-$170K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$158K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$132K |
OKUR Hedge Fund Activity: Q2 2022 in Review
33 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2022, worth a combined $43.3M — down 15% from $50.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of OKUR and 7 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $402K. The largest seller was Tybourne Capital Management, exiting entirely with an estimated $2.06M sold.
- 33 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $43.3M of OnKure Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
- 7 funds opened new OnKure Therapeutics positions in Q2 2022 and 14 closed out, a net change of -7 holders.
- The largest OnKure Therapeutics buyer in Q2 2022 was Citadel Advisors, an estimated $402K added.
- The largest OnKure Therapeutics seller in Q2 2022 was Tybourne Capital Management, an estimated $2.06M sold.
Based on aggregated 13F filings for Q2 2022.